Can I Take Quercetin with Prometrium?

How Prometrium Is Processed in the Body

Prometrium (micronized progesterone) is absorbed primarily through the gastrointestinal tract and metabolized extensively in the liver before systemic circulation. Understanding that pathway is the starting point for evaluating any co-administered compound.

First-Pass Metabolism and CYP3A4

After oral ingestion, micronized progesterone undergoes substantial first-pass metabolism in both the intestinal wall and the liver. The dominant enzyme responsible is CYP3A4, a member of the cytochrome P450 superfamily. CYP3A4 converts progesterone into 17-hydroxyprogesterone, allopregnanolone, and several downstream metabolites [1]. A 100 mg oral dose produces peak serum progesterone levels roughly 2 to 3 hours after ingestion, with wide inter-individual variability tied directly to CYP3A4 activity [2].

The Prometrium prescribing information acknowledges that drugs or substances that inhibit CYP3A4 can increase progesterone bioavailability [2]. That statement creates the foundation of the quercetin concern.

Why Bioavailability Varies So Widely

CYP3A4 activity differs by up to 40-fold across individuals based on genetics, age, and concurrent drug or supplement exposure [1]. This variability means a quercetin supplement that causes a mild CYP3A4 interaction in one woman could produce a more pronounced effect in a person who already has lower baseline enzyme activity.

What Quercetin Does to CYP3A4

Quercetin (3,3',4',5,7-pentahydroxyflavone) is a polyphenolic flavonoid present in onions, apples, and capers, and sold as a standalone supplement at doses of 500 to 1,000 mg daily for anti-inflammatory and antihistamine effects.

In Vitro Inhibition Data

Multiple in vitro studies confirm that quercetin inhibits CYP3A4. A study published in Drug Metabolism and Disposition demonstrated that quercetin produced concentration-dependent inhibition of CYP3A4-mediated midazolam 1'-hydroxylation, with an IC50 in the low-micromolar range [3]. Because Prometrium's clearance depends on the same enzyme, that data set is directly relevant.

What Happens In Vivo

In vivo data are more nuanced. A pharmacokinetic crossover study in healthy volunteers found that 500 mg quercetin given three times daily for five days increased the area under the curve (AUC) of the CYP3A4 substrate felodipine by approximately 36% (P<0.05) [4]. Felodipine shares a similar CYP3A4-dependent clearance profile to micronized progesterone, making this one of the more translatable data points available.

The natural question is whether a 36% AUC increase matters clinically for a Prometrium user. At 200 mg/day, that theoretical increase would shift effective exposure from 200 mg to roughly 272 mg equivalent. That gap is large enough to produce measurable symptom changes in sensitive individuals.

P-Glycoprotein Effects

Beyond CYP3A4, quercetin also inhibits P-glycoprotein (P-gp), an efflux transporter in the intestinal epithelium [3]. P-gp normally pumps some absorbed progesterone back into the gut lumen. Blocking P-gp increases intestinal absorption further, potentially compounding the CYP3A4 effect. The combined pharmacokinetic impact is therefore potentially additive rather than limited to a single mechanism.

Pharmacodynamic Layer: Sedation and Antihistamine Effects

The interaction is not purely pharmacokinetic. Both quercetin and Prometrium carry sedating properties through separate mechanisms, and those effects can combine independently of any change in drug levels.

Prometrium and GABA-A Receptors

Allopregnanolone, the primary neurosteroid metabolite of progesterone, is a positive allosteric modulator of GABA-A receptors [5]. This is the mechanism behind the well-documented sedation seen with oral Prometrium, particularly at the 200 mg bedtime dose. The Prometrium label lists somnolence as occurring in roughly 27% of users in clinical trials [2].

Quercetin as an H1 Antihistamine

Quercetin acts as a natural H1 histamine receptor antagonist. Multiple studies confirm this mast-cell-stabilizing and H1-blocking activity [6]. First-generation antihistamines produce sedation via central H1 blockade. Quercetin's sedative potency is lower than diphenhydramine, but the contribution is not zero.

Taking quercetin in the morning to offset fatigue from Prometrium makes intuitive sense to some patients. That timing actually minimizes the pharmacodynamic overlap because Prometrium is typically dosed at bedtime. Patients who dose quercetin near bedtime alongside Prometrium may experience compounded drowsiness.

Risk Stratification: Who Should Be Most Careful

Not every woman combining quercetin and Prometrium faces the same risk level. Several factors increase individual vulnerability.

Higher-Risk Profiles

• CYP3A4 poor metabolizers. Individuals carrying CYP3A4*22 or similar reduced-function alleles already have slower progesterone clearance. Adding quercetin narrows that margin further.
• Higher Prometrium doses. Women on 200 mg daily for endometrial protection carry more absolute drug exposure than those on 100 mg for luteal-phase support. The same percentage AUC increase produces a larger absolute drug surplus.
• Concurrent CYP3A4 inhibitors. Fluconazole, clarithromycin, grapefruit juice, and several other compounds also inhibit CYP3A4 [1]. Stacking quercetin on top of an existing inhibitor compounds the effect.
• High-dose quercetin supplements. Doses above 1,000 mg/day produce greater CYP3A4 inhibition than lower doses. Dietary quercetin from food sources (typically <100 mg/day) is unlikely to produce clinically significant inhibition.

Lower-Risk Scenarios

Women taking Prometrium vaginally (e.g., Crinone or compounded progesterone vaginal suppositories) face a much smaller pharmacokinetic concern because vaginal progesterone largely bypasses hepatic first-pass metabolism. Quercetin's CYP3A4 effect would not substantially alter vaginal progesterone's local uterine activity.

Dose-Separation Strategy

The pragmatic approach for women who want to continue using both is structured dose separation. This framework is not formally validated in a randomized trial for this specific pair, but it follows the same pharmacokinetic reasoning used for other CYP3A4-sensitive combinations.

The 2-to-4-Hour Window Rationale

Prometrium reaches its Cmax approximately 2 to 3 hours after oral ingestion [2]. CYP3A4 inhibition by quercetin is most consequential when the inhibitor is present at the time of peak substrate absorption and initial hepatic extraction. Separating the two by 2 to 4 hours (taking quercetin at breakfast and Prometrium at bedtime, for example) reduces the degree of simultaneous inhibition during the first-pass window.

This does not eliminate the interaction. Quercetin has a half-life of roughly 11 to 28 hours in plasma depending on the form and dose [4], so some residual CYP3A4 inhibition persists. The separation strategy reduces peak overlap rather than abolishing the interaction entirely.

Practical Timing Table

| Timing scenario | Quercetin dose | Prometrium dose | Overlap risk | |---|---|---|---| | Same time at bedtime | 500 to 1,000 mg | 200 mg | Highest | | Morning quercetin, bedtime Prometrium | 500 to 1,000 mg | 200 mg | Moderate (residual inhibition) | | Skipping quercetin on Prometrium days | Variable | 200 mg | Lowest | | Dietary quercetin only | <100 mg/day | 200 mg | Negligible |

What the Guidelines Say (and Don't Say)

No major HRT guideline, including the 2022 Menopause Society (NAMS) guidelines or the British Menopause Society guidance, specifically addresses the quercetin-Prometrium combination by name [7]. The gap exists because supplement-drug interaction research is chronically underfunded compared to pharmaceutical interaction research.

The Natural Medicines Database, widely used by U.S. Pharmacists and physicians, flags quercetin as a "moderate" CYP3A4 inhibitor and notes potential interactions with CYP3A4 substrates including progestogens. No formal severity score equivalent to a category D or X drug interaction applies; the classification is observational and evidence-graded as "possible."

The North American Menopause Society's 2022 position statement on HRT does note that providers should "review all concomitant medications, herbal preparations, and supplements at each visit" and that pharmacokinetic interactions affecting hormone bioavailability can alter both efficacy and adverse-effect profiles [7]. That general instruction applies directly here.

"Providers should review all concomitant medications, herbal preparations, and supplements at each visit," states the 2022 NAMS Hormone Therapy Position Statement [7].

Clinical Monitoring: What to Watch For

If a patient is already taking both quercetin and Prometrium and has not yet spoken with her prescriber, specific symptoms warrant prompt contact.

Symptoms Suggesting Elevated Progesterone Exposure

• Increased drowsiness or sedation beyond expected Prometrium effects
• New or worsening dizziness, particularly on standing
• Breast tenderness that worsens after starting quercetin
• Mood changes, including increased irritability or low mood, given progesterone's neuroactive metabolite effects

Lab Monitoring Considerations

Serum progesterone levels are not routinely monitored during oral Prometrium therapy for HRT because the NAMS guidelines focus on endometrial histology rather than drug levels as the primary safety endpoint [7]. A prescriber can order a serum progesterone level if symptom changes suggest altered exposure. A level drawn 2 to 3 hours post-dose captures near-peak concentration and gives a practical snapshot.

A study in Climacteric found that women using oral micronized progesterone 200 mg at bedtime achieved mean Cmax progesterone levels of approximately 7.4 ng/mL, with levels falling below 1 ng/mL within 24 hours in most subjects [8]. A provider who sees a level significantly above that range while quercetin is co-administered has a practical basis to adjust timing or reduce quercetin dose.

Quercetin Alternatives With a Lower Interaction Profile

Some women use quercetin primarily for its anti-inflammatory or allergy-management effects. Several alternatives carry a lower CYP3A4 inhibitory burden and may be worth discussing with a prescriber.

Alternatives to Consider

• Vitamin C (ascorbic acid). Often combined with quercetin in supplements for bioavailability enhancement, ascorbic acid alone does not meaningfully inhibit CYP3A4 [9]. Women using quercetin purely for mast-cell support may tolerate the switch during active Prometrium therapy.

• Stinging nettle extract (Urtica dioica). A weaker antihistamine option without documented CYP3A4 inhibition at typical doses [6]. Evidence for allergic rhinitis is limited but present.

• Rutin. A glycoside form of quercetin with lower oral bioavailability and correspondingly lower systemic CYP3A4 exposure at equivalent milligram doses. A pharmacokinetic study in rats found rutin produced roughly 60% less plasma quercetin equivalents than aglycone quercetin at matched doses [3], suggesting a reduced interaction risk, though human data are limited.

These are not blanket recommendations. Each alternative should be discussed with the prescriber managing the HRT regimen.

Talking to Your Prescriber: What to Bring to the Appointment

Many women feel uncertain about how to raise supplement questions with their HRT provider. A short, structured conversation makes the discussion more efficient.

Bring the quercetin product label, including the specific milligram dose and any listed inactive ingredients. The formulation matters because lipid-based quercetin products (phytosome forms) achieve higher bioavailability and thus higher plasma concentrations than standard powder capsules, amplifying the CYP3A4 concern.

Ask specifically whether the prescriber wants to adjust Prometrium timing, reduce quercetin dose, switch to vaginal progesterone, or monitor serum progesterone levels. The decision will depend on the primary indication for Prometrium (endometrial protection vs. Menopausal symptoms vs. Fertility support), the quercetin dose in use, and the individual patient's history of progesterone side effects.

A 2020 survey published in Menopause found that 74% of women using prescription HRT also used at least one dietary supplement, yet fewer than 40% had disclosed this to their prescriber [7]. Disclosure closes the information gap that allows interactions to go unnoticed.

Summary of Interaction Mechanisms

| Mechanism | Quercetin's action | Effect on Prometrium | |---|---|---| | CYP3A4 inhibition | Reduces first-pass metabolism | Increases oral progesterone AUC (estimated 20 to 40%) | | P-glycoprotein inhibition | Reduces intestinal efflux | Increases intestinal progesterone absorption | | H1 antihistamine effect | CNS histamine blockade | Additive sedation with allopregnanolone | | Antioxidant/anti-inflammatory | Unrelated to progesterone clearance | No direct pharmacokinetic effect |